Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.

Studied

A retrospective US database study compared tirzepatide with other GLP-1 receptor agonists for inflammatory bowel disease outcomes over 18 months.

Who / model

After matching, each group contained 3,042 adults; average age was 54.6 years and 71.3% were women.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Tirzepatide was associated with less intravenous steroid use and fewer combined steroid-or-surgery events. Hospitalization, emergency visits, intestinal surgery and adverse-outcome risks were similar between groups.

Limits

The authors call for prospective studies to validate these associations.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary